BA/BE Studies for Early Termination [Two-Stage / GS Designs]

posted by balakotu – India, 2015-09-22 15:05 (3487 d 23:49 ago) – Posting: # 15441
Views: 6,627

Dear all,

We are planning to conduct one "Replicate 4-period" bio-equivalence study with 70 subjects.

After completion of clinical phase we will analyze only 40 subjects.

If 40 subject’s data is shown bio-equivalent then we will stop the analysis of remaining 30 subjects. If the data is predictable then we will analyze remaining 30 subjects.

Please clarify whether this approach/design is acceptable to regulatory are not.

Regards

Kotu


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,422 posts in 4,927 threads, 1,668 registered users;
34 visitors (0 registered, 34 guests [including 9 identified bots]).
Forum time: 14:54 CEST (Europe/Vienna)

To know the history of science is to recognize the mortality
of any claim to universal truth.    Evelyn Fox Keller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5